The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis - (2023)
Pathogenetic mechanisms and therapeutic approaches of acute-to-chronic liver failure - (2023)
Acute-On-Chronic Liver Failure: Current Interventional Treatment Options and Future Challenges - (2020)
Myostatin is associated with the presence and development of acute-on-chronic liver failure - (2023)
Use and outcome of TIPS in hospitalized patients in Germany: A Nationwide study (2007-2018) - (2023)
Epidemiology of liver transplantation and post-LT complications in Germany: nationwide study (2005-2018) - (2023)
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial - (2023)
The Role of Hypoxia-Inducible Factor 1 Alpha in Acute-on-Chronic Liver Failure - (2024)
Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial - (2023)
Operating under pressure: Is there a place for preoperative TIPS? - (2024)
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 964590